Skip to main content

Advertisement

SpringerLink
Log in

Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part I: non-small cell lung cancer and breast cancer

  • Special Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Oligometastatic disease (OMD) defines a cancer status that is intermediate between localized and widely spread metastatic disease, and can be treated with curative intent. While diagnostic imaging tools have considerably improved in recent years, unidentified micrometastases can still evade current detection techniques, allowing the disease to progress. The various OMD scenarios are mainly defined by the number of metastases, the biological and molecular tumour profiles, and the timing of the development of metastases. Increasing knowledge has contributed to the earlier and improved detection of OMD, underlining the importance of early disease control. In view of increasing OMD detection rates in current real-world clinical practice and the lack of standardized evidence-based guidelines to treat this cancer status, a board of experts from the Spanish Societies of Radiation Oncology (SEOR) and Medical Oncology (SEOM) organized a series of sessions to update the current state-of-the-art on OMD from a multidisciplinary perspective, and to discuss how results from clinical studies might translate into promising treatment options. This expert review series summarizes what is known and what it is pending clarification in the context of OMD in the scenarios of non-small cell lung cancer and breast cancer (Part I), and prostate cancer and colorectal cancer (Part II), aiming to offer specialists a pragmatic framework to help improve patient management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10.

    Article  CAS  PubMed  Google Scholar 

  2. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8(6):378–82.

    Article  CAS  PubMed  Google Scholar 

  3. Lussier YA, Xing HR, Salama JK, Khodarev NN, Huang Y, Zhang Q, et al. MicroRNA expression characterizes oligometastasis(es). PLoS ONE. 2011;6(12): e28650.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Uppal A, Ferguson MK, Posner MC, Hellman S, Khodarev NN, Weichselbaum RR. Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs. Clin Exp Metastasis. 2014;31(6):735–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, et al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157–66.

    Article  PubMed  Google Scholar 

  6. Olson RA, Jiang W, Liu MC, Bergman A, Schellenberg D, Mou B, et al. Population based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: preliminary results of the SABR-5 trial. Int J Radiat Oncol. 2021;111(3):S4.

    Article  Google Scholar 

  7. Palma DA, Olson R, Harrow S, Correa RJM, Schneiders F, Haasbeek CJA, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer. 2019;19(1):816.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18–28.

    Article  PubMed  Google Scholar 

  9. Macdermed DM, Weichselbaum RR, Salama JK. A rationale for the targeted treatment of oligometastases with radiotherapy. J Surg Oncol. 2008;98(3):202–6.

    Article  PubMed  Google Scholar 

  10. Timmerman RD, Bizekis CS, Pass HI, Fong Y, Dupuy DE, Dawson LA, et al. Local surgical, ablative, and radiation treatment of metastases. CA Cancer J Clin. 2009;59(3):145–70.

    Article  PubMed  Google Scholar 

  11. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363(9422):1665–72.

    Article  PubMed  Google Scholar 

  12. Salama JK, Milano MT. Radical irradiation of extracranial oligometastases. J Clin Oncol. 2014;32(26):2902–12.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Palma D, Senan S. Stereotactic radiation therapy: changing treatment paradigms for stage I nonsmall cell lung cancer. Curr Opin Oncol. 2011;23(2):133–9.

    Article  PubMed  Google Scholar 

  14. Rusthoven KE, Hammerman SF, Kavanagh BD, Birtwhistle MJ, Stares M, Camidge DR. Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol. 2009;48(4):578–83.

    Article  CAS  PubMed  Google Scholar 

  15. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27(10):1572–8.

    Article  PubMed  Google Scholar 

  16. de Vin T, Engels B, Gevaert T, Storme G, De Ridder M. Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival. Ann Oncol. 2014;25(2):467–71.

    Article  PubMed  Google Scholar 

  17. Zayed S, Correa RJM, Palma DA. Radiation in the treatment of oligometastatic and oligoprogressive disease: rationale, recent data, and research questions. Cancer J. 2020;26(2):156–65.

    Article  PubMed  Google Scholar 

  18. Aparicio DZ, Requejo OH, de Julian MAC, Rodriguez CR, Leton PF. Local control rates in stereotactic body radiotherapy (SBRT) of lung metastases associated with the biologically effective dose. Rep Pract Oncol Radiother. 2019;24(2):142–50.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051–8.

    Article  PubMed  Google Scholar 

  20. Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020;38(25):2830–8.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Sogono P, Ball DL, Siva S. SABR-COMET: a new paradigm of care lights up the twilight of metastatic disease. Ann Transl Med. 2019;7(22):615.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Olson R, Mathews L, Liu M, Schellenberg D, Mou B, Berrang T, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial. BMC Cancer. 2020;20(1):380.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Palma DA, Louie AV, Rodrigues GB. New strategies in stereotactic radiotherapy for oligometastases. Clin Cancer Res. 2015;21(23):5198–204.

    Article  CAS  PubMed  Google Scholar 

  24. Szturz P, Nevens D, Vermorken JB. Oligometastatic disease management: finding the sweet spot. Front Oncol. 2020;10(2872): 617793.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Ashworth A, Rodrigues G, Boldt G, Palma D. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer. 2013;82(2):197–203.

    Article  PubMed  Google Scholar 

  26. Griffioen GH, Toguri D, Dahele M, Warner A, de Haan PF, Rodrigues GB, et al. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors. Lung Cancer. 2013;82(1):95–102.

    Article  PubMed  Google Scholar 

  27. Parikh RB, Cronin AM, Kozono DE, Oxnard GR, Mak RH, Jackman DM, et al. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014;89(4):880–7.

    Article  PubMed  Google Scholar 

  28. Mehta N, Mauer AM, Hellman S, Haraf DJ, Cohen EE, Vokes EE, et al. Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol. 2004;25(6):1677–83.

    PubMed  Google Scholar 

  29. Eberhardt WE, Mitchell A, Crowley J, Kondo H, Kim YT, Turrisi A, et al. The IASLC lung cancer staging project: proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2015;10(11):1515–22.

    Article  PubMed  Google Scholar 

  30. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51.

    Article  PubMed  Google Scholar 

  31. Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest. 2017;151(1):193–203.

    Article  PubMed  Google Scholar 

  32. Dingemans AC, Hendriks LEL, Berghmans T, Levy A, Hasan B, Faivre-Finn C, et al. Definition of synchronous oligometastatic non-small cell lung cancer-a consensus report. J Thorac Oncol. 2019;14(12):2109–19.

    Article  PubMed  Google Scholar 

  33. Yano T, Okamoto T, Haro A, Fukuyama S, Yoshida T, Kohno M, et al. Local treatment of oligometastatic recurrence in patients with resected non-small cell lung cancer. Lung Cancer. 2013;82(3):431–5.

    Article  PubMed  Google Scholar 

  34. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv192-237.

    Article  CAS  PubMed  Google Scholar 

  35. Collaud S, Stahel R, Inci I, Hillinger S, Schneiter D, Kestenholz P, et al. Survival of patients treated surgically for synchronous single-organ metastatic NSCLC and advanced pathologic TN stage. Lung Cancer. 2012;78(3):234–8.

    Article  PubMed  Google Scholar 

  36. Ashworth AB, Senan S, Palma DA, Riquet M, Ahn YC, Ricardi U, et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer. 2014;15(5):346–55.

    Article  PubMed  Google Scholar 

  37. Schanne DH, Heitmann J, Guckenberger M, Andratschke NHJ. Evolution of treatment strategies for oligometastatic NSCLC patients—a systematic review of the literature. Cancer Treat Rev. 2019;80: 101892.

    Article  PubMed  Google Scholar 

  38. Basler L, Kroeze SG, Guckenberger M. SBRT for oligoprogressive oncogene addicted NSCLC. Lung Cancer. 2017;106:50–7.

    Article  CAS  PubMed  Google Scholar 

  39. Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA Jr, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7(12):1807–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Magnuson WJ, Lester-Coll NH, Wu AJ, Yang TJ, Lockney NA, Gerber NK, et al. Management of brain metastases in tyrosine kinase inhibitor-naive epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis. J Clin Oncol. 2017;35(10):1070–7.

    Article  CAS  PubMed  Google Scholar 

  41. Yu HA, Sima CS, Huang J, Solomon SB, Rimner A, Paik P, et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2013;8(3):346–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Gan GN, Weickhardt AJ, Scheier B, Doebele RC, Gaspar LE, Kavanagh BD, et al. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int J Radiat Oncol Biol Phys. 2014;88(4):892–8.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, et al. Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. Clin Cancer Res. 2018;24(24):6195–203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Xu Q, Zhou F, Liu H, Jiang T, Li X, Xu Y, et al. Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs. J Thorac Oncol. 2018;13(9):1383–92.

    Article  PubMed  Google Scholar 

  45. Elamin YY, Gomez DR, Antonoff MB, Robichaux JP, Tran H, Shorter MK, et al. Local consolidation therapy (LCT) after first line tyrosine kinase inhibitor (TKI) for patients with EGFR mutant metastatic non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 2019;20(1):43–7.

    Article  CAS  PubMed  Google Scholar 

  46. Chan OSH, Lam KC, Li JYC, Choi FPT, Wong CYH, Chang ATY, et al. ATOM: a phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI. Lung Cancer. 2020;142:41–6.

    Article  PubMed  Google Scholar 

  47. Elamin Y, Gandhi S, Antonoff M, Mott F, Gibbons DL, Le X, et al. BRIGHTSTAR: a pilot trial of local consolidative therapy (LCT) with brigatinib in tyrosine kinase inhibitor (TKI)-naïve ALK-rearranged advanced NSCLC. J Clin Oncol. 2020;38(15_suppl):9624–9624.

    Article  Google Scholar 

  48. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, et al. Non-Small Cell Lung cancer, Version 5, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(4):504–535. https://jnccn.org/view/journals/jnccn/15/4/article-p504.xml. Last access 28 Nov 2022.

  49. Wang XS, Bai YF, Verma V, Yu RL, Tian W, Ao R, et al. Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated NSCLC. J Natl Cancer Inst. 2022. https://doi.org/10.1093/jnci/djac015.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105(4):256–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Demaria S, Coleman CN, Formenti SC. Radiotherapy: changing the game in immunotherapy. Trends Cancer. 2016;2(6):286–94.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Weichselbaum RR, Liang H, Deng L, Fu YX. Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol. 2017;14(6):365–79.

    Article  CAS  PubMed  Google Scholar 

  53. Popp I, Grosu AL, Niedermann G, Duda DG. Immune modulation by hypofractionated stereotactic radiation therapy: therapeutic implications. Radiother Oncol. 2016;120(2):185–94.

    Article  CAS  PubMed  Google Scholar 

  54. Yang H, Jin T, Li M, Xue J, Lu B. Synergistic effect of immunotherapy and radiotherapy in non-small cell lung cancer: current clinical trials and prospective challenges. Precis Clin Med. 2019;2(1):57–70.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Torok JA, Salama JK. Combining immunotherapy and radiotherapy for the STAR treatment. Nat Rev Clin Oncol. 2019;16(11):666–7.

    Article  PubMed  Google Scholar 

  56. Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18(7):895–903.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Bauml JM, Mick R, Ciunci C, Aggarwal C, Davis C, Evans T, et al. Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: a phase 2 trial. JAMA Oncol. 2019;5(9):1283–90.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Welsh JW, Menon H, Tang C, Verma V, Altan M, Hess KR, et al. Randomized phase I/II trial of pembrolizumab with and without radiotherapy for metastatic non-small cell lung cancer. J Clin Oncol. 2019;37(15):9104–9104.

    Article  Google Scholar 

  59. Jiang JM, Kabarriti R, Brodin NP, Ohri N, Guha C, Kalnicki S, et al. Stereotactic radiosurgery with immunotherapy is associated with improved overall survival in patients with metastatic melanoma or non-small cell lung cancer: a National Cancer Database analysis. Clin Transl Oncol. 2022;24(1):104–11.

    Article  CAS  PubMed  Google Scholar 

  60. Chicas Sett R, Zafra Martin J, Castilla Martinez JF, Morales I, Rodriguez D, Benitez G, et al. Immuno-SABR reboots the immune response in patients with metastatic NSCLC and melanoma in progression to anti-PD-1 therapy. Int J Radiat Oncol. 2020;108(3):S73–4.

    Article  Google Scholar 

  61. Patel JD, Bestvina CM, Karrison T, Jelinek MJ, Juloori A, Pointer K, et al. Randomized phase I trial to evaluate concurrent or sequential ipilimumab, nivolumab, and stereotactic body radiotherapy in patients with stage IV non-small cell lung cancer (COSINR Study). J Clin Oncol. 2020;38(15_suppl):9616–9616.

    Article  Google Scholar 

  62. Turajlic S, Swanton C. Metastasis as an evolutionary process. Science. 2016;352(6282):169–75.

    Article  CAS  PubMed  Google Scholar 

  63. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494–500.

    Article  CAS  PubMed  Google Scholar 

  64. Ning MS, Gomez DR, Heymach JV, Swisher SG. Stereotactic ablative body radiation for oligometastatic and oligoprogressive disease. Transl Lung Cancer Res. 2019;8(1):97–106.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Spaggiari L, Bertolaccini L, Facciolo F, Gallina FT, Rea F, Schiavon M, et al. A risk stratification scheme for synchronous oligometastatic non-small cell lung cancer developed by a multicentre analysis. Lung Cancer. 2021;154:29–35.

    Article  CAS  PubMed  Google Scholar 

  66. Schonewolf CA, Verma V, Post CM, Berman AT, Frick MA, Vachani A, et al. Outcomes of invasive mediastinal nodal staging versus positron emission tomography staging alone for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy. Lung Cancer. 2018;117:53–9.

    Article  PubMed  Google Scholar 

  67. Uhlig J, Case MD, Blasberg JD, Boffa DJ, Chiang A, Gettinger SN, et al. Comparison of survival rates after a combination of local treatment and systemic therapy vs systemic therapy alone for treatment of stage IV non-small cell lung cancer. JAMA Netw Open. 2019;2(8): e199702.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12):1672–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37(18):1558–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4(1): e173501.

    Article  PubMed  Google Scholar 

  71. Blake-Cerda M, Lozano-Ruiz F, Maldonado-Magos F, de la Mata-Moya D, Diaz-Garcia D, Lara-Mejia L, et al. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: a prospective phase 2 study. Lung Cancer. 2021;152:119–26.

    Article  CAS  PubMed  Google Scholar 

  72. Kang HY, Moon SH, Song IH. A unique bleeding-related complication of sorafenib, a tyrosine kinase inhibitor, in advanced hepatocellular carcinoma: a case report. J Med Case Reports. 2014;8:72–72.

    Article  Google Scholar 

  73. Kwapisz D. Oligometastatic breast cancer. Breast Cancer. 2019;26(2):138–46.

    Article  PubMed  Google Scholar 

  74. Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andre F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623–49.

    Article  CAS  PubMed  Google Scholar 

  75. Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2017;26(6):809–15.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Cheng YC, Ueno NT. Improvement of survival and prospect of cure in patients with metastatic breast cancer. Breast Cancer. 2012;19(3):191–9.

    Article  PubMed  Google Scholar 

  77. Niibe Y, Kuranami M, Matsunaga K, Takaya M, Kakita S, Hara T, et al. Value of high-dose radiation therapy for isolated osseous metastasis in breast cancer in terms of oligo-recurrence. Anticancer Res. 2008;28(6B):3929–31.

    PubMed  Google Scholar 

  78. Dawood S, Broglio K, Ensor J, Hortobagyi GN, Giordano SH. Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol. 2010;21(11):2169–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, et al. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? Br J Cancer. 2015;112(9):1445–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Hassett MJ, Uno H, Cronin AM, Carroll NM, Hornbrook MC, Ritzwoller DP. Comparing survival after recurrent vs de novo stage IV advanced breast, lung, and colorectal cancer. JNCI Cancer Spectr. 2018;2(2):pky024.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Gradishar WJ, Moran MS, Abraham J, Aft, R, Agnese D, allison KH, et al. Breast Cancer, Version 3, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;20(6):691–722. https://jnccn.org/view/journals/jnccn/20/6/article-p691.xml. Last access 28 Nov 2022.

  82. Gera R, Chehade H, Wazir U, Tayeh S, Kasem A, Mokbel K. Locoregional therapy of the primary tumour in de novo stage IV breast cancer in 216 066 patients: a meta-analysis. Sci Rep. 2020;10(1):2952.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Lee JS, Toktas O, Soran A. Role of locoregional treatment in de novo stage IV breast cancer. Clin Med Insights Oncol. 2020;14:1179554920942440.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Norton L, Massague J. Is cancer a disease of self-seeding? Nat Med. 2006;12(8):875–8.

    Article  CAS  PubMed  Google Scholar 

  85. Comen E, Norton L, Massague J. Clinical implications of cancer self-seeding. Nat Rev Clin Oncol. 2011;8(6):369–77.

    Article  PubMed  Google Scholar 

  86. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449(7162):557–63.

    Article  CAS  PubMed  Google Scholar 

  87. Campbell MJ, Scott J, Maecker HT, Park JW, Esserman LJ. Immune dysfunction and micrometastases in women with breast cancer. Breast Cancer Res Treat. 2005;91(2):163–71.

    Article  CAS  PubMed  Google Scholar 

  88. Danna EA, Sinha P, Gilbert M, Clements VK, Pulaski BA, Ostrand-Rosenberg S. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res. 2004;64(6):2205–11.

    Article  CAS  PubMed  Google Scholar 

  89. Makhlin I, Fox K. Oligometastatic breast cancer: is this a curable entity? A contemporary review of the literature. Curr Oncol Rep. 2020;22(2):15.

    Article  PubMed  PubMed Central  Google Scholar 

  90. AlSendi M, O’Reilly D, Zeidan YH, Kelly CM. Oligometastatic breast cancer: are we there yet? Int J Cancer. 2021;149(8):1520–8.

    Article  CAS  PubMed  Google Scholar 

  91. Cortes J, Gebhart G, Ruiz Borrego M, Stradella A, Bermejo B, Escrivá S, et al. Chemotherapy (CT) de-escalation using an FDG-PET/CT (F-PET) and pathological response-adapted strategy in HER2[+] early breast cancer (EBC): PHERGain trial. J Clin Oncol. 2020;38(15_suppl):503–503.

    Article  Google Scholar 

  92. Pérez-García JM, Gebhart G, Ruiz Borrego M, Stradella A, Bermejo B, Schmid P, et al. Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. Lancet Oncol. 2021;22(6):858–71.

    Article  PubMed  Google Scholar 

  93. Garcia-Murillas I, Chopra N, Comino-Mendez I, Beaney M, Tovey H, Cutts RJ, et al. Assessment of molecular relapse detection in early-stage breast cancer. JAMA Oncol. 2019;5(10):1473–8.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015;7(302):302ra133.

    Article  PubMed  Google Scholar 

  95. Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519–30.

    Article  CAS  PubMed  Google Scholar 

  96. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–21.

    Article  CAS  PubMed  Google Scholar 

  97. Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817–28.

    Article  PubMed  Google Scholar 

  98. Rossi V, Berchialla P, Giannarelli D, Nistico C, Ferretti G, Gasparro S, et al. Should all patients with HR-positive HER2-negative metastatic breast cancer receive CDK 4/6 inhibitor as first-line based therapy? A network meta-analysis of data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT trials. Cancers (Basel). 2019;11(11):1661.

    Article  CAS  PubMed  Google Scholar 

  99. Yang Y, Luo J, Chen X, Yang Z, Mei X, Ma J, et al. CDK4/6 inhibitors: a novel strategy for tumor radiosensitization. J Exp Clin Cancer Res. 2020;39(1):188.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Lin C, Wu J, Ding S, Goh C, Andriani L, Lu S, et al. Subdivision of M1 stage for de novo metastatic breast cancer to better predict prognosis and response to primary tumor surgery. J Natl Compr Canc Netw. 2019;17(12):1521–8.

    Article  PubMed  Google Scholar 

  101. Adam R, Aloia T, Krissat J, Bralet MP, Paule B, Giacchetti S, et al. Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg. 2006;244(6):897–907 (discussion 907–8).

    Article  PubMed  PubMed Central  Google Scholar 

  102. Bale R, Putzer D, Schullian P. Local treatment of breast cancer liver metastasis. Cancers. 2019. https://doi.org/10.3390/cancers11091341.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Shien T. The eligibility of primary tumor resection for de novo stage IV breast cancer patients. Transl Cancer Res. 2018. https://doi.org/10.21037/tcr.2018.05.28.

    Article  Google Scholar 

  104. Soran A, Ozmen V, Ozbas S, Karanlik H, Muslumanoglu M, Igci A, et al. Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: protocol MF07-01. Ann Surg Oncol. 2018;25(11):3141–9.

    Article  PubMed  Google Scholar 

  105. Kobayashi T, Ichiba T, Sakuyama T, Arakawa Y, Nagasaki E, Aiba K, et al. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review. Breast Cancer. 2012;19(3):218–37.

    Article  PubMed  Google Scholar 

  106. Cha C, Ahn SG, Yoo TK, Kim KM, Bae SJ, Yoon C, et al. Local treatment in addition to endocrine therapy in hormone receptor-positive and HER2-negative oligometastatic breast cancer patients: a retrospective multicenter analysis. Breast Care. 2020;15(4):408–14.

    Article  PubMed  Google Scholar 

  107. van Ommen-Nijhof A, Steenbruggen TG, Schats W, Wiersma T, Horlings HM, Mann R, et al. Prognostic factors in patients with oligometastatic breast cancer—a systematic review. Cancer Treat Rev. 2020;91: 102114.

    Article  PubMed  Google Scholar 

  108. Steinauer K, Gross MW, Huang DJ, Eppenberger-Castori S, Guth U. Radiotherapy in patients with distant metastatic breast cancer. Radiat Oncol. 2014;9:126.

    Article  PubMed  PubMed Central  Google Scholar 

  109. Jutzy JMS, Lemons JM, Luke JJ, Chmura SJ. The evolution of radiation therapy in metastatic breast cancer: from local therapy to systemic agent. Int J Breast Cancer. 2018;2018:4786819.

    Article  PubMed  PubMed Central  Google Scholar 

  110. McGuire SE, Gonzalez-Angulo AM, Huang EH, Tucker SL, Kau SW, Yu TK, et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2007;68(4):1004–9.

    Article  PubMed  PubMed Central  Google Scholar 

  111. Lian CL, Guo LY, Zhang L, Wang J, Lei J, Hua L, et al. Aggressive local treatment improves survival in stage IV breast cancer with synchronous metastasis. Front Oncol. 2020;10: 522580.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Zhang J, Luo S, Qiu Z, Lin Y, Song C. Impact of postoperative radiotherapy on survival of patients with de novo stage IV breast cancer: a population-based study from the SEER database. Front Oncol. 2021;11(619): 625628.

    Article  PubMed  PubMed Central  Google Scholar 

  113. Donlon NE, Power R, Hayes C, Reynolds JV, Lysaght J. Radiotherapy, immunotherapy, and the tumour microenvironment: turning an immunosuppressive milieu into a therapeutic opportunity. Cancer Lett. 2021;502:84–96.

    Article  CAS  PubMed  Google Scholar 

  114. Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021;11(11):5365–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Milano MT, Zhang H, Metcalfe SK, Muhs AG, Okunieff P. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat. 2009;115(3):601–8.

    Article  PubMed  Google Scholar 

  116. Krug D, Vonthein R, Illen A, Olbrich D, Barkhausen J, Richter J, et al. Metastases-directed radiotherapy in addition to standard systemic therapy in patients with oligometastatic breast cancer: study protocol for a randomized controlled multi-national and multi-center clinical trial (OLIGOMA). Clin Transl Radiat Oncol. 2021;28:90–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Tsoutsou PG, Zaman K, Martin Lluesma S, Cagnon L, Kandalaft L, Vozenin MC. Emerging opportunities of radiotherapy combined with immunotherapy in the era of breast cancer heterogeneity. Front Oncol. 2018;8:609.

    Article  PubMed  PubMed Central  Google Scholar 

  118. Muraro E, Furlan C, Avanzo M, Martorelli D, Comaro E, Rizzo A, et al. Local high-dose radiotherapy induces systemic immunomodulating effects of potential therapeutic relevance in oligometastatic breast cancer. Front Immunol. 2017;8:1476.

    Article  PubMed  PubMed Central  Google Scholar 

  119. Chmura SJ, Winter KA, Al-Hallaq HA, Borges VF, Jaskowiak NT, Matuszak M, et al. NRG-BR002: a phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer (NCT02364557). J Clin Oncol. 2019;37(15):TPS1117–TPS1117.

    Article  Google Scholar 

  120. Perez-Garcia J, Cortez P, Gion M, Cortes J. Can we cure oligometastatic disease? A practical point of view. Curr Opin Oncol. 2020;32(6):568–74.

    Article  PubMed  Google Scholar 

  121. Nguyen AT, Shiao SL, McArthur HL. Advances in combining radiation and immunotherapy in breast cancer. Clin Breast Cancer. 2021;21(2):143–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Elamin YY, Antonoff M, Blakely C, Baggstorm M, Bivona T, Le X, et al. Randomized phase II trial of osimertinib with or without local consolidation therapy (LCT) for patients with EGFR-mutant metastatic NSCLC (NORTHSTAR). Ann Oncol. 2018;29:viii547.

    Article  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Dr Álvaro Rodríguez-Lescure (former president of SEOM) and Dr Jorge Contreras Martínez (former president of SEOR) who facilitated the organization of the “I Jornada Virtual de Consenso SEOM-SEOR sobre el Abordaje Multidisciplinar de la Enfermedad Oligometastásica”, and Dr Juan de la Haba Rodríguez. (SEOM), Dr Manel Algara López (SEOR), Dr Ana Fernández Montes (SEOM), and Dr Carmen Rubio Rodríguez (SEOR) for their valuable contribution as moderators of the sessions. The authors would also like to thank Dr Susana Cañón-Sánchez (from Statistics Consulting S.L., Valencia, Spain) for providing scientific support and medical writing services.

Funding

This work was funded by SEOR and SEOM.

Author information

Authors and Affiliations

  1. Radiation Oncology Department, Hospital Ruber Internacional, C. de La Masó, 38, 28034, Madrid, Spain

    Aurora Rodríguez Pérez

  2. Medical Oncology Department, Hospital Universitario del Vall d’Hebron, Barcelona, Spain

    Enriqueta Felip Font

  3. Department of Radiation Oncology, ASCIRES Grupo Biomédico, Valencia, Spain

    Rodolfo Chicas-Sett

  4. Radiation Oncology Department, Hospital Universitario HM Sanchinarro, Madrid, Spain

    Ángel Montero-Luis & Ovidio Hernando Requejo

  5. Medical Oncology Department, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain

    Laura de Paz Arias

  6. Medical Oncology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain

    Aránzazu González-del-Alba

  7. Radiation Oncology Department, Hospital Ramón y Cajal, Madrid, Spain

    Fernando López-Campos

  8. Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Carlos López López

  9. Radiation Oncology Department, Hospital La Fe, Valencia, Spain

    Antonio José Conde-Moreno

  10. Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain

    José Ángel Arranz Arija

  11. Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain

    Javier de Castro Carpeño

Authors
  1. Aurora Rodríguez Pérez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Enriqueta Felip Font
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rodolfo Chicas-Sett
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ángel Montero-Luis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Laura de Paz Arias
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Aránzazu González-del-Alba
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Fernando López-Campos
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Carlos López López
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ovidio Hernando Requejo
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Antonio José Conde-Moreno
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. José Ángel Arranz Arija
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Javier de Castro Carpeño
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors were involved in the conception of this work, drafting and/or revising the manuscript, and approved the final version.

Corresponding author

Correspondence to Aurora Rodríguez Pérez.

Ethics declarations

Conflict of interest

EFF has received consultancy honoraria from Amgen, Astrazeneca, Bayer, Bristol Myers Squibb, Daiichi Dankyo, Eli Lilly, F. Hoffmann-La Roche, Glaxo Smith Kline, Janssen, Merck Sharp and Dome, Merck Serono, Novartis, Peptomyc, Pfizer, Sanofi and Takeda; and speaker honoraria from Amgen, Astrazeneca, Bristol Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Janssen, Medscape, Merck Sharp and Dome, Peervoice, Pfizer, Medical Trends, Merck Serono, Sanofi, Takeda and TouchOncology; RCh-S, has received honoraria for speaking engagements from Astrazeneca, Fresenius-Kabi, Grunenthal and Adventia Pharma; and declares financial relationship with Fresenius-Kabi and Adventia Pharma. AGdA, has received research funding from Astellas, travel grants from Astellas, Jansen, Sanofi, BMS, Roche, Pfizer, MSD and Ipsen; and honoraria for speaking engagements, membership of advisory boards and continuing medical education from Janssen, Astellas, Sanofi, Bayer, Roche, Ipsen, BMS, MSD, Pfizer, Merck, Eusa Pharma, Eisai and Astra Zeneca. JAA has received speaker honoraria from Astellas Pharma, Pfizer and Bristol-Myers Squibb, and consultancy fees from Pfizer, Astellas Pharma, Janssen-Cilag, MSD Oncology, BMS, Merck, AstraZeneca, Bayer, Eisai and Novartis. JdCC has received consultancy fees from AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Hoffmann- La Roche and Takeda. All other authors declare no relevant financial or non-financial interests to disclose.

Ethical approval and Informed consent

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rodríguez Pérez, A., Felip Font, E., Chicas-Sett, R. et al. Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part I: non-small cell lung cancer and breast cancer. Clin Transl Oncol 25, 882–896 (2023). https://doi.org/10.1007/s12094-022-03011-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-022-03011-6

Keywords

Search

Navigation